Abstract:Botulinum neurotoxins (BoNT) inhibit neuroexocytosis, leading to the potentially lethal disease botulism. BoNT serotype A is responsible for most human botulism cases, and there are no approved therapeutics to treat already intoxicated patients. A growing body of research has demonstrated that BoNT/A can escape into the central nervous system, and therefore, identification of BoNT/A inhibitors that can penetrate BBB and neutralize the toxin within intoxicated neurons would be important. We previously identified an FDA‐approved, orally bioavailable compound, KX2‐391 (Tirbanibulin) that inhibits BoNT/A in motor neuron assays. Recently, a structural analog of KX2‐391, KX2‐361, has been shown to exhibit good oral bioavailability and cross BBB with high efficiency in mouse experiments. Therefore, in this work, we evaluated the inhibitory effects of KX2‐361 against BoNT/A. Toward this goal, we first evaluated the compound for its effects on cell viability in PC12 cells, via MTT assay, and in mouse embryonic stem cell (mESC)‐derived motor neurons, with imaging‐based assays. Following, we tested KX2‐361 in mESC‐derived motor neurons intoxicated with BoNT/A holotoxin, and the compound exhibited activity against the toxin in both pre‐ and post‐intoxication conditions. Excitingly, KX2‐361 also inhibited BoNT/A enzymatic component (light chain; LC) in PC12 cells transfected with BoNT/A LC. Furthermore, our molecular docking analyses suggested that KX2‐361 can directly bind to BoNT/A LC. Medicinal chemistry approaches to develop structural analogs of KX2‐361 to increase its efficacy against BoNT/A may provide a critical lead compound with BBB penetration capacity for drug development efforts against BoNT/A intoxication.

Discovery of a Potent Botulinum Neurotoxin A Inhibitor ZM299 with Effective Protections in Botulism Mice

Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication Studies

Designing, synthesis and evaluation of derived analogues of selected small molecule non-peptidic inhibitors against serotype BoNT/ F

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

A New Neutralizing Antibody Against Botulinum Neurotoxin B Recognizes the Protein Receptor Binding Sites for Synaptotagmins II.

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Unilateral Whisker Pad Injection of Botulinum Toxin Type a Enhances Spatial Learning in Mice.

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E

Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E

Tirbanibulin (KX2‐391) analog KX2‐361 inhibits botulinum neurotoxin serotype A mediated SNAP‐25 cleavage in pre‐ and post‐intoxication models in cells

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity

Selection of Candidate Monoclonal Antibodies for Therapy of Botulinum Toxin Type A Intoxications

Design and evaluation of mRNA encoding recombinant neutralizing antibodies for botulinum neurotoxin type B intoxication prophylaxis

Botulinum neurotoxin X lacks potency in mice and in human neurons

Advances in Research on Mechanisms of Action of Botulinum Neurotoxins

Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice

Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A

Cell-Penetrating Botulinum Neurotoxin Type A With Improved Cellular Uptake and Therapeutic Index

Botulinum neurotoxins: Future innovations